1
Home
Companies

Carbylan Therapeutics

Carbylan Therapeutics
Leadership team

Thomas Andrew Crockett (CEO & Director)

Edward W. Unkart (Independent Director)

Albert Cha (Independent Director)

Products/ Services
Health Care, Health Diagnostics, Therapeutics
Number of Employees
0 - 50
Headquarters
Palo Alto, California, United States
Established
2005
Company Registration
SEC CIK number: 0001348911
Traded as
NASDAQ:CBYL
Social Media
URL
www.carbylan.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Carbylan Therapeutics is a San Francisco-based biopharmaceutical company focused on the development of novel treatments for diseases associated with inflammation and cell adhesion. The company was founded in 2002 and its lead product is a novel small molecule for the potential treatment of acute kidney injury (AKI).
History

Carbylan Therapeutics was founded in 2002 by Dr. David Anderson and Dr. David Sosnovik, two veteran scientists from the biopharmaceutical industry. Since then, the company has grown to a leading player in the field of inflammation and cell adhesion, with a focus on developing cutting-edge treatments. Carbylan’s core research developed a novel small molecule that can be used to treat acute kidney injury (AKI). The company’s product portfolio also includes treatments for inflammatory eye diseases and metabolic diseases.

Mission
Carbylan Therapeutics’ mission is to develop novel treatments and cures for diseases associated with inflammation and cell adhesion using cutting-edge technology to ensure maximum safety and effectiveness.
Vision
Carbylan Therapeutics seeks to become a leader in the treatment of diseases associated with inflammation and cell adhesion. We are committed to providing safer and more effective treatments for our patients, utilizing our cutting-edge technology.
Key Team

Tomas Kiselak (Board Observer)

Bong Y. Koh (Board Observer)

Brian J. G. Pereira (Independent Chairman)

Nancy Stuart (Independent Director)

Patrick A. Treanor (Independent Director)

Recognition and Awards
Carbylan Therapeutics has received numerous awards and accolades from biotech industries, including the 2019 ReAwards for Innovation in Biotech and a 2019 Golden Goose Award for its pioneering work in developing treatments for AKI.
References

https://in.investing.com/equities/carbylan-therapeutics-inc

https://www.crunchbase.com/organization/carbylan-biosurgery

www.carbylan.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Carbylan Therapeutics
Leadership team

Thomas Andrew Crockett (CEO & Director)

Edward W. Unkart (Independent Director)

Albert Cha (Independent Director)

Products/ Services
Health Care, Health Diagnostics, Therapeutics
Number of Employees
0 - 50
Headquarters
Palo Alto, California, United States
Established
2005
Company Registration
SEC CIK number: 0001348911
Traded as
NASDAQ:CBYL
Social Media
URL
www.carbylan.com